MirenaMirena is an IUD that was approved in January 2000 for contraception and later in 2009 was approved for control of menstruation. It is not regulated as a device by the FDA because of meds it releases and is approved under the food drug and cosmetic act section 505 (b). It is manufactured by Bayer and unlike most contraceptives it does not contain estrogen.
Mirena is recommended for use in woman that has had at least one child. It is inserted into the uterus and should be removed after five years. The Mirena label does not warn for spontaneous migration & risk of perforation aside from the time of implantation (this label has since been slightly modified in May 2014). Lawyers are looking for injuries that demonstrate that the device had migrated after implantation resulting in perforation of the uterus and/or embedment requiring surgical removal.
TestosteroneLawyers are pursuing Testosterone therapy cases where male users of testosterone have suffered stroke, heart attacks, and blood clots such as PEs and DVTs. AndroGel and other “T” treatments such as Axiron (Eli Lilly); Androderm (Actavis Inc.); Fortesta (Endo Pharm); Striant (Actient Pharm); Testim (Auxilium Pharm) which are available as testosterone gels, patches, pellets and injections, are linked to an increased risk of cardiac problems in older and middle-aged men and in younger men with a history of heart disease.
A Jan 29, 2014 study confirmed prior studies demonstrating this increased risk. On Jan. 31, 2014, the FDA announced it would be investigating the risk of heart attack, stroke and death in men using prescription testosterone products. In June 2014, the FDA said it is requiring testosterone drug manufacturers to include a wider warning about the increased risk of blood clots in the veins.